• Intercept Pharmaceuticals Inc., of New York, said it completed a $30 million Series C preferred stock financing led by OrbiMed Advisors LLC, with existing majority investor Genextra S.p.A. also participating.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter